Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)

Competitors to Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)

Cellectar Biosciences, Inc. 

Cellectar Biosciences is developing targeted therapies for cancer treatment using its proprietary phospholipid drug conjugate (PDC) platform. Their focus on delivering drugs specifically to cancer cells competes directly with Alpha Tau's targeted treatment approach. While Cellectar is in the early stages of bringing its therapies to market, their innovative technology could pose a significant threat should they secure favorable clinical results and regulatory approvals, giving them potential competitive strength.

Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics is focused on cell therapy for cancer, utilizing tumor-infiltrating lymphocyte (TIL) therapy. This sets a distinct therapy method against Alpha Tau Medical's approach with alpha radiation therapy. Although both companies are in the oncology sector, Iovance's leading edge lies in its clinical trials and potential FDA approvals for advanced treatments, positioning itself strongly in the market for solid tumor therapy.

Medtronic plc 

Medtronic plc offers a variety of oncology therapies, including innovative drug delivery systems. Though their primary focus includes surgical and device-based solutions, they also face Alpha Tau Medical regarding treatments for cancer pain management. Medtronic’s extensive research and development capabilities allow them to innovate more rapidly than smaller companies, giving them a competitive edge in securing market share and partnerships within the oncology space.

Novocure Limited 

Novocure Limited is in the oncology space and offers a unique treatment modality known as Tumor Treating Fields (TTFields). While Alpha Tau Medical focuses on a different modality with its alpha radiation therapy for solid tumors, both companies are vying for the same patient demographics and oncologists' attention. Novocure's established presence and clinical evidence for its TTFields in treating glioblastoma give it a competitive advantage as it has a proven track record and wide acceptance among clinical practitioners.

OncoSec Medical Incorporated

OncoSec Medical is engaged in developing intratumoral immunotherapy, which aims to induce systemic immune responses against cancer. Their approach, while differing fundamentally from Alpha Tau's alpha therapy, positions them in the same cancer treatment market where competition for oncologists' attention and resources is fierce. OncoSec's innovative technology has shown promise in early-stage trials, but it still trails behind Alpha Tau in terms of established clinical validation and market presence.